Cookie sul sito Web di KCI
Usiamo i cookie per migliorare l'esperienza di esplorazione del nostro sito Web. Per ulteriori informazioni sui cookie ed il loro utilizzo, visitare la pagine Informativa sulla privacy. Per una migliore esplorazione, si consiglia di accettare l'uso dei cookie.
Aiuto accessibilità | Mappa del sito | Contatto | Assistenza clienti
Home  |  Patologie  |  Prodotti  |  Evidenze cliniche  |  Formazione e Training  |  Per i pazienti  |  Assistenza clienti
Siete qui Home > Notizie e Media > Acelity Acquires SNaP® Disposable Negative Pressure Wound Therapy System to Expand Offering in Portable, Non-Powered NPWT Technology

Acelity Acquires SNaP® Disposable Negative Pressure Wound Therapy System to Expand Offering in Portable, Non-Powered NPWT Technology

Distribuzione : 1 Dicembre 2015

Acquisition accelerates Acelity’s strategy in the disposable negative pressure wound therapy market

KCI, Leader in Advanced Wound Care Solutions

SAN ANTONIO, Dec. 1, 2015 – Acelity, a global wound care and regenerative medicine company, announced it has acquired the SNaP® Therapy System, a disposable negative pressure wound therapy (NPWT) line of products from Spiracur, a privately-held medical device company based in Sunnyvale, Calif. SNaP® Therapy System is designed to treat a range of complex and hard-to-heal wounds with portable, non-powered negative pressure technology, primarily in the post-acute setting. The acquisition will allow Acelity’s industry-leading sales and service channels to support the expansion of the SNaP® Therapy System to patients and their care teams around the world who need access to NPWT devices. Terms of the deal were not disclosed.


The acquisition of the SNaP® business  accelerates Acelity’s plans for disposable NPWT and increases access to the post-acute market by strengthening the company’s portfolio of offerings for customers in need of comprehensive wound care solutions. This transaction amplifies the largest range of disposable negative pressure solutions while expanding patient access to these devices through Acelity’s more than 1,800 sales professionals across North America and other developed markets. The broadened Acelity portfolio has the potential to significantly alter advanced wound care outside the U.S. as portable, disposable NPWT solutions offer a more economical approach to treating chronic wounds in those geographies.


“As an organization, we continually seek out opportunities to fulfill our vision of restoring people’s lives through advancements in wound care technology,” said Joe Woody, president and chief executive officer of Acelity. “The addition of the SNaP® System complements our existing suite of clinically-proven products that speed healing and reduce costs to health systems around the world. We will continue to develop and enhance our offerings through innovation and acquisitions to remain at the forefront of healing solutions.” 


SNaP® technology offers simple, off the shelf, easy-to-use products and may improve the patient experience due to its size, weight and ability to be discreet, helping mobile patients to return to their normal lives.


For more than 20 years, Acelity has been the worldwide leader in NPWT and has built the largest portfolio of advanced wound therapeutic products in the industry. Acelity has expanded its flagship V.A.C.® Therapy technology, bringing forth revolutionary solutions such as V.A.C. VeraFlo™ Therapy, the only instillation therapy on the market, which cleanses, treats and heals wounds, combining the proven benefits of NPWT with instillation therapy. In addition, Acelity’s proprietary SensaT.R.A.C.™ Technology – the only of its kind – monitors pressure at the wound site and adjusts accordingly to ensure the selected negative pressure is maintained. With the addition of SNaP® Therapy System to the company’s portfolio, Acelity has the broadest range of disposable NPWT products in the world.


“Looking ahead, we are well positioned to build upon our trusted and innovative portfolio of solutions to include near adjacencies such as easy-to-use dressings and other complementary products,” said Woody. “Working with clinicians across the continuum of care, we are expanding our focus to ensuring therapy compliance with technologies such as remote monitoring and telehealth elements that will leverage our deep knowledge and expertise.”


About Acelity

Acelity L.P. Inc. and its subsidiaries are a global advanced wound care and regenerative medicine company created by uniting the strengths of three companies, Kinetic Concepts, Inc., LifeCell Corporation and Systagenix Wound Management, Limited. Available in more than 75 countries, the innovative and complementary Acelity product portfolio delivers value through solutions that speed healing and lead the industry in quality, safety and customer experience. Headquartered in San Antonio, Texas, Acelity employs more than 5,700 people around the world.

  • Condividi su
  • Condividi su Twitter
  • Visita il nostro canale su YouTube

Messaggi importanti per i pazienti

Avviso legale | Informativa sulla privacy | Contatto

KCI Medical S.r.l. con socio unico (soggetta a direzione e coordinamento di KCI UK Holdings Ltd.)
Capitale sociale 4.900.000 Euro (i.v.) – P.IVA / C.F. 10804870151 – Registro Imprese MI n. 330579 – REA/CCIAA MI 1406540

Le informazioni contenute in questo sito sono destinate esclusivamente agli operatori sanitari.

Le informazioni contenute in questo sito si intendono solo per i clienti italiani.

© 1998 – 2013 KCI Licensing, Inc. Tutti i diritti riservati.    DSL#09-02-193.IT
Le informazioni incluse in questo sito Web sono state concepite esclusivamente per l’Italia. Il presente sito Web contiene informazioni su prodotti che possono non essere disponibili nei diversi paesi e possono non aver ricevuto l'approvazione o l'autorizzazione all'immissione sul mercato dagli enti regolatori governativi per indicazioni o restrizioni diverse a seconda dei paesi.